Management of asymptomatic anthracycline-induced cardiac damage after treatment for childhood cancer: A postal survey among Dutch adult and pediatric cardiologists

Journal of Pediatric Hematology/Oncology

Volumn 27, Issue 6, 2005, Pages 319-322

  Van Dalen, Elvira C ^a   Van Der Pal, Heleen J H ^b   Reitsma, Johannes B ^b   De Winter, Robbert J ^b   Helbing, Wim A ^c   Ottenkamp, Jaap ^d   Caron, Huib N ^a   Kremer, Leontien C M ^a  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^d Center for Congenital Anomalies of the Heart   (Netherlands)

Author keywords

Anthracyclines; Cardiotoxicity; Childhood cancer survivors; Drug therapy; Survey

Indexed keywords

ANTHRACYCLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; CANCER SURVIVAL; CHILDHOOD CANCER; HEALTH SURVEY; HEART INJURY; HUMAN; NETHERLANDS; PRIORITY JOURNAL; QUESTIONNAIRE;

ADULT; AGE FACTORS; ANTHRACYCLINES; CHILD; FOLLOW-UP STUDIES; HEALTH CARE SURVEYS; HEART; HUMANS; MYOCARDIUM; NEOPLASMS; NETHERLANDS; POSTAL SERVICE; QUESTIONNAIRES; SPECIALTIES, MEDICAL;

EID: 21244482151     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mph.0000170887.27958.27     Document Type: Article

References (12)

1. Dutch Cancer Registry. Childhood cancer in the Netherlands 1989-1997. Utrecht: Vereniging van Integrale Kankercentra, 2000.
2. Heikens J. Childhood cancer and the price of cure: studies on late effects of childhood cancer treatment. Thesis, University of Amsterdam, Amsterdam, 2000.
3. Kremer LCM, Caron HN. Anthracycline cardiotoxicity in children. N Engl J Med. 2004;351:120-121.
4. Steinherz LJ, Graham T, Hurwitz R, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Children's Cancer Study Group. Pediatrics. 1992;89:942-949.
5. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-691.
6. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol. 2002;20:4517-4522.
7. Silber JH, Cnaan A, Clark BJ, et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol. 2004;22:820-828.
8. Van Dalen EC, Van der Pal HJH, Van den Bos C, et al. Treatment for asymptomatic anthracycline-induced cardiac dysfunction in childhood cancer survivors: the need for evidence. J Clin Oncol. 2003;21:3377.
9. Lipshultz SE. Cardiovascular trials in long-term survivors of childhood cancer. J Clin Oncol. 2004;22:769-773.
10. Steinherz LJ, Steinherz PG, Tan CT, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991;266:1672-1677.
11. Pfisterer ME, Battler A, Zaret BL. Range of normal values for left and right ventricular ejection fraction at rest and during exercise assessed by radionuclide angiocardiography. Eur Heart J. 1985;6:647-655.
12. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001;22:1527-1560.